$海普瑞(SZ002399)$ Second-quarter Lovenox® sales increased 24.6% to €367 million, were driven by strong sales in Europe (up 43.3%) and Rest of the World (up 13.8%) reflecting the recovery in hospital procedures and continued benefit from the WHO guidelines recommending the use of low molecular weight heparins in hospitalized COVID-19 patients, more than offsetting biosimilar competition in Europe.
全部讨论
nemo1012021-07-30 13:42赛诺菲原料库存也不多了，上下游的价格博弈可能就要见分晓了。疫情遥遥无期，我更看好上游原料厂商胜出。
熬鹰2021-07-30 13:3221H1,26亿销售收入有望，期待赛诺菲下半年高位补库存。
邓刚钓鱼就是飞2021-07-30 13:04呵呵，卵用？
邓刚钓鱼就是飞2021-07-30 13:04已经两年采购少了
pedaler海2021-07-30 12:39国内的供应商只能是海普瑞和健友，不知道海普瑞和赛诺菲的合同谈得怎样？
nemo1012021-07-30 12:36绝大部分来着中国。过去一年采购较少，其实就是在于中国供应商博弈价格。
pedaler海2021-07-30 12:23赛诺菲的肝素原料药来自哪里？
pedaler海2021-07-30 12:21伊诺肝素制剂很畅销，海普瑞的增长不会比赛诺菲的少吧？整个欧盟伊诺肝素制剂上半年的数据有没有？
nemo1012021-07-30 11:56赛诺菲是低分子量肝素钠制剂销售的真正王者。赛诺菲的销量变化才是最好的风向标。
熬鹰2021-07-30 11:42strong sales in Europe (up 43.3%)